Cooley M&A

OCTOBER 24, 2024

According to SRS Acquiom’s 2023 Life Sciences M&A Study , 91% of private bio/pharma deals, 59% of private medical device deals, and 47% of private diagnostics and research technologies deals in the study included an earnout between 2021 and 2023. Comparatively, just 21% of non-life sciences deals included an earnout in the same period.

Beta 52

Beta Alpha Marketability Technology 52

Value Scope

SEPTEMBER 24, 2020

As companies continue to legitimately integrate ESG into business strategy, the ability to achieve “alpha,” which is an excess return or performance above a codified index or peer group, might become more difficult to do. Technology. Unsuccessful investment in new technologies. Adjustments to Beta can accomplish this.

Intangible Assets 130

Intangible Assets Alpha Beta Marketability 130

Musings on Markets

JANUARY 10, 2025

Breaking down companies by (S&P) sector, again both in numbers and market cap, here is what I get: While industrials the most listed stocks, technology accounts for 21% of the market cap of all listed stocks, globally, making it the most valuable sector. Beta & Risk 1. Return on Equity 1. Debt Ratios & Fundamentals 1.

Risk Premium 119

Risk Premium Dividends Start-ups Corporate Finance 119